Dr. Robert Ruxer, MD
What this data tells you about Dr. Ruxer
Dr. Robert Ruxer is a medical oncology specialist in Fort Worth, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ruxer performed 36,222 Medicare services across 2,300 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ruxer received a total of $452 from 9 pharmaceutical and/or device companies across 15 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ruxer is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 15,300 | $43 | $137 |
| Azacitidine chemotherapy injection | 7,120 | $0 | $13 |
| Paclitaxel chemotherapy injection | 4,218 | $0 | $8 |
| Anti-nausea injection (fosaprepitant) | 2,700 | $0 | $5 |
| Dexamethasone injection (steroid) | 750 | $0 | $1 |
| Blood draw (venipuncture) | 743 | $8 | $20 |
| Comprehensive metabolic blood panel | 707 | $10 | $64 |
| Complete blood count (CBC) with differential | 691 | $8 | $36 |
| Injection, granisetron hydrochloride, 100 mcg | 470 | $0 | $24 |
| Office visit, established patient (30-39 min) | 438 | $94 | $368 |
| Anti-nausea injection (Aloxi/palonosetron) | 250 | $1 | $114 |
| Lactate dehydrogenase (enzyme) level | 189 | $6 | $31 |
| Administration of chemotherapy into vein, 1 hour or less | 181 | $101 | $707 |
| Injection, zoledronic acid, 1 mg | 162 | $7 | $431 |
| Injection, carboplatin, 50 mg | 156 | $2 | $300 |
| Injection of additional new drug or substance into vein | 150 | $12 | $108 |
| Office visit, established patient (20-29 min) | 111 | $65 | $250 |
| Magnesium level test | 107 | $6 | $29 |
| Ferritin level test (iron stores) | 106 | $13 | $60 |
| Iron level test | 105 | $6 | $27 |
| Iron binding capacity test | 105 | $8 | $35 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 101 | $57 | $211 |
| Reticulated (young) platelet measurement | 89 | $35 | $143 |
| Drug injection, under skin or into muscle | 81 | $11 | $96 |
| Microscopic examination for white blood cells with manual cell count | 76 | $4 | $22 |
| Complete blood count (CBC), automated | 76 | $6 | $34 |
| Injection, diphenhydramine hcl, up to 50 mg | 76 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 73 | $49 | $313 |
| Immunoglobulin level test | 72 | $9 | $56 |
| Vitamin B-12 level test | 60 | $15 | $76 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 53 | $134 | $3,675 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 52 | $22 | $157 |
| Hospital follow-up visit, high complexity | 45 | $91 | $357 |
| Red blood count, automated test | 44 | $4 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 44 | $48 | $344 |
| Unclassified drugs | 43 | $1 | $9 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $27 | $145 |
| Urinalysis with microscopic exam | 40 | $3 | $28 |
| Administration of chemotherapy into vein, each additional hour | 40 | $21 | $161 |
| Infusion into a vein for hydration, each additional hour | 35 | $10 | $75 |
| Measurement of immunoglobulin light chains | 32 | $17 | $60 |
| Hospital follow-up visit, moderate complexity | 32 | $62 | $247 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 31 | $1,163 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 30 | $90 | $657 |
| New patient office visit (45-59 min) | 29 | $121 | $565 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 27 | $16 | $100 |
| Infusion, normal saline solution , 1000 cc | 26 | $2 | $19 |
| PSA test (prostate cancer screening) | 25 | $18 | $94 |
| Office visit, established patient, complex (40-54 min) | 25 | $140 | $496 |
| Advance care planning consultation, first 30 min | 22 | $65 | $292 |
| Carcinoembryonic antigen (cea) protein level | 17 | $19 | $99 |
| Injection of drug or substance into vein | 13 | $26 | $247 |
| Thyroid stimulating hormone (TSH) test | 12 | $16 | $80 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (67%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Ruxer is a mixed practice specialist, with above-average Medicare volume (top 24% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Ruxer experienced with pembrolizumab injection (keytruda)?
Does Dr. Ruxer receive payments from pharmaceutical companies?
How do Dr. Ruxer's costs compare to other medical oncologists in Fort Worth?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology